Search

everythinglearnresearchcommunity

for

Search:↓

Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.

Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.

Sorafenib can cause delayed skin problems, so patients need careful monitoring.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Sonidegib effectively treated advanced basal cell carcinoma with mild side effects.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Erlotinib can cause unexpected side effects like eyelash growth and scarring.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Sorafenib may cause hair loss in a way similar to alopecia areata.

The treatment is safe and shows promise for metastatic breast cancer.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.

Pexidartinib often causes liver issues and fatigue, especially in women.

Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Many patients on new leukemia drugs had mild to moderate skin reactions.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

Effective treatment for UFT overdose includes antibiotics and G-CSF, with bone marrow biopsy and transfusion as backup options.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Gefitinib can cause rare scarring hair loss.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.